Updates in HCM Management: An Expert Interpretation of the ESC Cardiomyopathy Guidelines 2023

Published: 31 August 2023

  • Views:

    Views Icon 14392

  • Likes:

    Heart Icon 7
  • episode_image
    29m 46s
    Part 3 Q&A Juan-Pablo Kaski, Elena Arbelo
Average (ratings)
No ratings
Your rating
Register or Login to View PDF

Overview

This programme features the chairpersons responsible for the most recent ESC Guidelines on Cardiomyopathy, which were presented at ESC 2023 in Amsterdam.

 

Prof Elena Arbelo (University of Barcelona, ES) and Prof Juan Pablo Kaski (University College London, UK) offer comprehensive insights into the updated guidelines. They delve into the latest developments in hypertrophic cardiomyopathy (HCM), provide treatment recommendations for obstructive hypertrophic cardiomyopathy (oHCM), and discuss how these new guidelines impact the current approach to managing these conditions.

 

This session is tailored to assist healthcare practitioners in comprehending the most recent guidelines recommendations and ensuring their effective implementation. The authors explore how medical practices can adapt to incorporate new therapeutic agents for oHCM and clarify the responsibilities associated with prescribing these therapies.

 

This programme holds particular educational value for Cardiologists, Heart Failure Specialists, Electrophysiologists, and Cardiac Surgeons. Furthermore, it will be of interest to any HCPs specialising in HCM treatment or those who may play a role within the broader care team by identifying and referring patients for specialist assessments on a global scale.

 

 

Watch the CME accredited version

 

This programme is supported through an educational grant from Bristol Myers Squibb.

Learning Objectives

  • Recall guideline updates relevant to the use of disease modifying agents in hypertrophic cardiomyopathy
  • Identify patients who, according to guidelines, may benefit from emerging disease modifying therapies prior to septal ablation therapy or being managed by symptom control alone
  • Discuss long-term management strategies for patients receiving myosin inhibitor therapy

Target Audience

  • Cardiologists
  • Heart Failure Specialists
  • Electrophysiologists
  • Cardiac Surgeons
  • HCPs who specialise in treating HCM

More from this programme

Part 1

What’s New for HCM?

Prof Elena Arbelo and Prof Juan Pablo Kaski reveal updated HCM guidelines, offer oHCM treatment insights, and discuss condition management.

1 session
What’s New for HCM? Watch now

Part 2

Practical Implications for Practitioners

This session is designed to help healthcare professionals understand the latest guidelines recommendations and effectively implement them.

1 session
Practical Implications for Practitioners Watch now

Part 3

Q&A

Prof Elena Arbelo and Prof Juan Pablo Kaski address the audience's questions and examine further the topic of HCM Management. 

1 session
Q&A Watch now

Part 4

Downloadable Asset

1 session
Download the Key Updates Infographic Watch now

Faculty Biographies

Juan-Pablo Kaski

Juan-Pablo Kaski

Associate Professor

Prof Kaski is an Associate Professor at the Centre for Inherited Cardiovascular Diseases, UCL, London, UK. He is also a consultant paedriatric cardiologist, and Director of the Inherited Cardiovascular Diseases Unit at the Great Ormond Street Hospital for Children NHS Trust, UK. 

For his work on the genetic basis of pre-adolescent hypertrophic cardiomyopathy, Prof Kaski was awarded the Young Investigator Award by the European Society of Cardiology (ESC) in 2008.

Prof Kaski's research interests include cardiomyopathies, inherited arrhythmias, aortopathy syndromes and rare cardiovascular genetic diseases. His main focuses include heart muscle disease, ion channel diseases, sudden cardiac death and Marfan syndrome. 

Prof Juan-Pablo Kaski is on the Editorial Board of European Cardiology Review, in addition to other leading journals.

View full profile
Elena Arbelo

Elena Arbelo

Associate Professor

Prof Elena Arbelo is a Cardiac Electrophysiologist at Hospital Clínic of Barcelona, Barcelona, Spain, where she serves as Coordinator of the Cardiac Genetic Diseases and Sudden Arrhythmic Death Unit.

She is a Clinical Professor at the University of Barcelona and a researcher at the Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS). Prof Arbelo is a member of several committees of the European Society of Cardiology (ESC), the European Heart Rhythm Association (EHRA), and the Heart Rhythm Society (HRS).

Prof Arbelo is a committee member for several large-scale European Registries to gather data on atrial fibrillation and guideline implementation. She serves as a member of the Working Group on Atrial Fibrillation of the International Consortium for Health Outcomes Measurement (ICHOM). 

Prof Arbelo is an editorial board member of Arrhythmia & Electrophysiology Review journal. 

 

View full profile

Comments

You must be to comment. If you are not registered, you can register here.